Algorae Pharmaceuticals Ltd (1AI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has a cash flow conversion efficiency ratio of -0.327x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-618.21K ≈ $-437.42K USD) by net assets (AU$1.89 Million ≈ $1.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Algorae Pharmaceuticals Ltd (1AI) defensive interval to measure how many days the company can operate on defensive assets alone.
Algorae Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Algorae Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Landmarks Bhd
KLSE:1643
|
-0.010x |
|
Australian Agricultural Projects Ltd
AU:AAP
|
0.124x |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
0.058x |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
0.029x |
|
Viva Gold Corp
V:VAU
|
-0.063x |
|
Xintela AB
ST:XINT
|
0.242x |
|
Rougier S.A.
PA:ALRGR
|
0.055x |
|
Hancom MDS Inc
KQ:086960
|
0.040x |
Annual Cash Flow Conversion Efficiency for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Algorae Pharmaceuticals Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Algorae Pharmaceuticals Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$2.23 Million ≈ $1.58 Million |
AU$-785.25K ≈ $-555.61K |
-0.352x | -22.91% |
| 2024-06-30 | AU$5.31 Million ≈ $3.76 Million |
AU$-1.52 Million ≈ $-1.08 Million |
-0.287x | +16.52% |
| 2023-06-30 | AU$5.78 Million ≈ $4.09 Million |
AU$-1.99 Million ≈ $-1.41 Million |
-0.343x | +32.16% |
| 2022-06-30 | AU$4.03 Million ≈ $2.85 Million |
AU$-2.04 Million ≈ $-1.44 Million |
-0.506x | +52.31% |
| 2021-06-30 | AU$1.38 Million ≈ $974.40K |
AU$-1.46 Million ≈ $-1.03 Million |
-1.061x | +1.77% |
| 2020-06-30 | AU$2.88 Million ≈ $2.04 Million |
AU$-3.11 Million ≈ $-2.20 Million |
-1.080x | -124.63% |
| 2019-06-30 | AU$4.14 Million ≈ $2.93 Million |
AU$-1.99 Million ≈ $-1.41 Million |
-0.481x | +3.88% |
| 2018-06-30 | AU$7.14 Million ≈ $5.05 Million |
AU$-3.57 Million ≈ $-2.53 Million |
-0.500x | -11.63% |
| 2017-06-30 | AU$7.52 Million ≈ $5.32 Million |
AU$-3.37 Million ≈ $-2.38 Million |
-0.448x | +19.40% |
| 2016-06-30 | AU$5.68 Million ≈ $4.02 Million |
AU$-3.16 Million ≈ $-2.23 Million |
-0.556x | +20.52% |
| 2015-06-30 | AU$5.13 Million ≈ $3.63 Million |
AU$-3.59 Million ≈ $-2.54 Million |
-0.700x | -7056.25% |
| 2014-06-30 | AU$8.43 Million ≈ $5.97 Million |
AU$-82.44K ≈ $-58.33K |
-0.010x | -109.69% |
| 2013-06-30 | AU$13.25 Million ≈ $9.38 Million |
AU$1.34 Million ≈ $946.01K |
0.101x | +158.23% |
| 2012-06-30 | AU$14.35 Million ≈ $10.16 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.173x | +79.53% |
| 2011-06-30 | AU$6.76 Million ≈ $4.78 Million |
AU$-5.72 Million ≈ $-4.05 Million |
-0.847x | +9.92% |
| 2010-06-30 | AU$6.24 Million ≈ $4.41 Million |
AU$-5.86 Million ≈ $-4.15 Million |
-0.940x | +8.93% |
| 2009-06-30 | AU$5.53 Million ≈ $3.91 Million |
AU$-5.70 Million ≈ $-4.04 Million |
-1.032x | -111.67% |
| 2008-06-30 | AU$11.48 Million ≈ $8.13 Million |
AU$-5.60 Million ≈ $-3.96 Million |
-0.487x | +87.66% |
| 2007-06-30 | AU$1.40 Million ≈ $991.53K |
AU$-5.54 Million ≈ $-3.92 Million |
-3.951x | -7.34% |
| 2006-06-30 | AU$1.80 Million ≈ $1.27 Million |
AU$-6.61 Million ≈ $-4.68 Million |
-3.681x | -89.36% |
| 2005-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-6.09 Million ≈ $-4.31 Million |
-1.944x | -302.54% |
| 2004-06-30 | AU$-1.33 Million ≈ $-937.82K |
AU$-1.27 Million ≈ $-900.02K |
0.960x | -- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more